Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Novartis : U.S. Patents Awarded to Inventors in Virginia (Feb. 24)

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2017 | 09:06pm CET

Targeted News Service Targeted News Service

ALEXANDRIA, Va., Feb. 24 -- The following federal patents were awarded to inventors in Virginia.


Alcon Research, Fort Worth, Texas, Assigned Patent for Use of PEO-PBO Block Copolymers

ALEXANDRIA, Va., Feb. 24 -- Alcon Research, Fort Worth, Texas, has been assigned a patent (9,574,160) developed by two co-inventors for the "use of PEO-PBO block copolymers in ophthalmic compositions." The co-inventors are Howard Allen Ketelson, Dallas, and Nathaniel D. McQueen, Vienna, Virginia.

The patent application was filed on Nov. 16, 2010 (12/947,614). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=95,74,160.PN.&OS=PN/95,74,160&RS=PN/95,74,160

Written by Amal Ahmed; edited by Sudarshan Harpal.


Dell Products, Round Rock, Texas, Assigned Patent for Single Sign-On System for Shared Resource Environments

ALEXANDRIA, Va., Feb. 24 -- Dell Products, Round Rock, Texas, has been assigned a patent (9,576,140) developed by two co-inventors for a "single sign-on system for shared resource environments." The co-inventors are Peter E. Ghostine, Vienna, Virginia, and Michael McDonald, Herndon, Virginia.

The patent application was filed on Aug. 24, 2012 (13/594,273). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,576,140.PN.&OS=PN/9,576,140&RS=PN/9,576,140

Written by Deviprasad Jena; edited by Sudarshan Harpal.

Myron Struck, editor, Targeted News Service, Springfield, Va., 703/304-1897; editor@targetednews.com; http://www.targetednews.com


(c) 2017 Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
02/24 NOVARTIS : U.S. Patents Awarded to Inventors in Virginia (Feb. 24)
02/24 NOVARTIS AG : Blog Coverage Novartis Gains Priority Review from the FDA for its ..
02/24 NOVARTIS : receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-posi..
02/24 NOVARTIS : Patent Issued for Methods of Nuclease-Based Genetic Engineering (USPT..
02/23 NOVARTIS : drug Zykadia receives FDA Priority Review for first-line use in patie..
02/22 MANUFACTURING DELAY OF GENERIC DRUG : PFE) A Relief For Teva Pharmaceutical Ind..
02/16 JOHNSON & JOHNSON : Nancy-Ann DeParle and Dr. Scott Gottlieb Join Executives fro..
02/15 NOVARTIS : Sources Sought Notice - Alcon Wavecards
02/14 IMMUNICUM : Appoints Karin Hoogendoorn as Head of CMC
02/09 NOVARTIS : Patent Issued for Microscope-Less Wide Field-Of-View Surgical OCT Vis..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 European advisory committee positive actions
02/23 FDA to accelerate review of Novartis' marketing application for Zykadia in fi..
02/22 Momenta Delay Means Race For Copaxone Generic Is On
02/21 HEPATITIS B MARKET : Emerging Players Could Make The Difference
02/21 Merck Provides Keytruda For Bionomics Phase 1 Trial On Combination With BNC10..
Financials ($)
Sales 2017 48 441 M
EBIT 2017 11 334 M
Net income 2017 7 521 M
Debt 2017 16 963 M
Yield 2017 3,69%
P/E ratio 2017 23,33
P/E ratio 2018 20,48
EV / Sales 2017 4,53x
EV / Sales 2018 4,29x
Capitalization 202 648 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 30
Average target price 80,4 $
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG4.72%202 648
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
MERCK & CO., INC.11.86%182 412
SANOFI4.79%109 848
More Results